REPLIMUNE GROUP INC

Replimune Group Inc.’s stock has experienced significant fluctuations, raising questions about the company’s financial health and strategic direction amidst its pioneering work in oncolytic immunotherapy.

Replimune Group Inc’s stock price surged 10.9% to $8.14, driven by growing investor confidence in the company’s oncolytic immunotherapy treatments and the expanding intra-tumoral cancer therapies market.